EXEL
Price
$36.65
Change
-$0.39 (-1.05%)
Updated
Apr 3, 02:37 PM (EDT)
Capitalization
10.37B
40 days until earnings call
ORMP
Price
$2.19
Change
-$0.01 (-0.45%)
Updated
Apr 3, 02:49 PM (EDT)
Capitalization
89.87M
55 days until earnings call
Ad is loading...

EXEL vs ORMP

Header iconEXEL vs ORMP Comparison
Open Charts EXEL vs ORMPBanner chart's image
Exelixis
Price$36.65
Change-$0.39 (-1.05%)
Volume$888
Capitalization10.37B
Oramed Pharmaceuticals
Price$2.19
Change-$0.01 (-0.45%)
Volume$100
Capitalization89.87M
EXEL vs ORMP Comparison Chart
Loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EXEL vs. ORMP commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and ORMP is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (EXEL: $37.04 vs. ORMP: $2.20)
Brand notoriety: EXEL: Notable vs. ORMP: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EXEL: 70% vs. ORMP: 22%
Market capitalization -- EXEL: $10.37B vs. ORMP: $89.87M
EXEL [@Biotechnology] is valued at $10.37B. ORMP’s [@Biotechnology] market capitalization is $89.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EXEL’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • EXEL’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, EXEL is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EXEL’s TA Score shows that 3 TA indicator(s) are bullish while ORMP’s TA Score has 3 bullish TA indicator(s).

  • EXEL’s TA Score: 3 bullish, 4 bearish.
  • ORMP’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, EXEL is a better buy in the short-term than ORMP.

Price Growth

EXEL (@Biotechnology) experienced а +0.08% price change this week, while ORMP (@Biotechnology) price change was -6.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.84%. For the same industry, the average monthly price growth was -9.88%, and the average quarterly price growth was -14.17%.

Reported Earning Dates

EXEL is expected to report earnings on May 13, 2025.

ORMP is expected to report earnings on May 28, 2025.

Industries' Descriptions

@Biotechnology (-7.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EXEL($10.4B) has a higher market cap than ORMP($89.9M). EXEL (21.05) and ORMP (20.91) have similar P/E ratio . EXEL YTD gains are higher at: 11.231 vs. ORMP (-9.091). EXEL has higher annual earnings (EBITDA): 719M vs. ORMP (9.44M). EXEL has more cash in the bank: 1.11B vs. ORMP (142M). ORMP has less debt than EXEL: ORMP (429K) vs EXEL (191M). EXEL has higher revenues than ORMP: EXEL (2.17B) vs ORMP (0).
EXELORMPEXEL / ORMP
Capitalization10.4B89.9M11,568%
EBITDA719M9.44M7,618%
Gain YTD11.231-9.091-124%
P/E Ratio21.0520.91101%
Revenue2.17B0-
Total Cash1.11B142M782%
Total Debt191M429K44,522%
FUNDAMENTALS RATINGS
EXEL vs ORMP: Fundamental Ratings
EXEL
ORMP
OUTLOOK RATING
1..100
6983
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
22100
SMR RATING
1..100
4085
PRICE GROWTH RATING
1..100
4161
P/E GROWTH RATING
1..100
9045
SEASONALITY SCORE
1..100
n/a36

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (68) in the Pharmaceuticals Other industry is in the same range as EXEL (76) in the Biotechnology industry. This means that ORMP’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for ORMP (100) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew significantly faster than ORMP’s over the last 12 months.

EXEL's SMR Rating (40) in the Biotechnology industry is somewhat better than the same rating for ORMP (85) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew somewhat faster than ORMP’s over the last 12 months.

EXEL's Price Growth Rating (41) in the Biotechnology industry is in the same range as ORMP (61) in the Pharmaceuticals Other industry. This means that EXEL’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for EXEL (90) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EXELORMP
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
65%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 15 days ago
65%
Bullish Trend 28 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
62%
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPYG81.620.67
+0.83%
SPDR® Portfolio S&P 500 Growth ETF
KNCT101.550.53
+0.53%
Invesco Next Gen Connectivity ETF
JEMA38.530.04
+0.10%
JPMorgan ActiveBuilders EM Eq ETF
FLKR18.61-0.03
-0.16%
Franklin FTSE South Korea ETF
EDD4.74-0.02
-0.42%
Morgan Stanley Emerging Markets Domestic Debt Fund

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.79%
SRPT - EXEL
36%
Loosely correlated
+0.90%
ALNY - EXEL
34%
Loosely correlated
+4.33%
TECH - EXEL
33%
Poorly correlated
+1.80%
MRSN - EXEL
32%
Poorly correlated
+1.68%
ORMP - EXEL
32%
Poorly correlated
+3.29%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+3.29%
BTAI - ORMP
44%
Loosely correlated
+3.65%
INO - ORMP
44%
Loosely correlated
+10.67%
MBIO - ORMP
44%
Loosely correlated
+11.36%
VERV - ORMP
44%
Loosely correlated
-5.44%
ZNTL - ORMP
43%
Loosely correlated
-2.52%
More